1Semana·

$ABBV (+0,32 %)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway


$BMY (-0,03 %) Bristol-Myers Squibb seems to benefits from this +13%

10
11 Comentarios

Should it go down another 10%-15% at $ABBV: 🛒🛒🛒🛒
9
Imagen de perfil
If AbbVie goes down even further, I might spontaneously get in today ^^
3
Ver todas las 4 respuestas adicionales
Imagen de perfil
Am in
2
Imagen de perfil
Hach, 30% at $BMY in 6 months. I can live with that 🥳😎
2
Imagen de perfil
stupid :(
Imagen de perfil
Gut :)
Hm... in my overview AbbVie is shown with minus 20%. If I go to the share with minus 12% ... 🤷‍♀️ is this a known error or what is the reason for this? 🤷‍♀️
Únase a la conversación